| Week 0 | Week 2 | P* | Week 4 | P | |
|---|---|---|---|---|---|
| BILAG-MSK n (%) | |||||
| A | 6/16 (37.5) | 3/16 (18.7) | 1/16 (0.06) | ||
| B | 6/16 (37.5) | 3/16 (18.7 | 2/16 (12.5) | ||
| C | 4/16 (25) | 5/16 (31.2) | 6/16 (37.5) | ||
| D | 0/16 (0) | 5/16 (31.2) | 6/16 (37.5) | ||
| BILAG improved, n (%) | N/A | 10/16 (62.5) | 13/16 (81) | ||
| SLEDAI MSK Criterion = 4 points, | |||||
| n (%) | 14/16 (87.5) | 10 /16 (62.5) | 9 /16 (56) | ||
| SLEDAI improved, n (%) | 4/14 (28.5) | 5/14 (36) | |||
| TJC (0–28), median (IQR) | 8 (4.3–12.3) | 4 (1.0 −13.5) | 0.228 | 4 (1–14.8) | 0.197 |
| SJC (0–28), median (IQR) | 3 (0.3–5) | 0 (0–1) | 0.059 | 0 (0–0) | 0.003 |
| Symptomatic joints, median (IQR) | 15 (5.8–21.5) | 2 (0–13) | 0.047 | 3.5 (1–14.8) | 0.066 |
| Patient VAS (0–100), median (IQR) | 55 (30–78.5) | 30 (8.8–40) | 0.016 | 35 (10–48.8) | 0.059 |
| Physician VAS (0–100), median (IQR) | 31 (13–65.5) | 23 (5–50) | 0.001 | 21 (3.8–43.5) | 0.001 |
| US- total PD, median (IQR) | 8.5 (4.8–34.8) | 1 (0–6.3) | 0.002 | 1 (0–1) | 0.001 |
| US-total GS, median (IQR) | 24 (17–46) | 12.5 (5.3–23.8) | 0.002 | 10.5 (7–13.8) | 0.001 |
| No. joints with synovitis, median (IQR) | 8 (5–19.3) | 3 (0.8–7.5) | 0.004 | 2 (1–4) | 0.001 |
P values compare 2 and 4 weeks with baseline. Value under 0.05 considered as trend, values under 0.025 considered significant.